They demonstrated that tumor-derived RECQL4 inhibits the activation of the DC cGAS-STING pathway, thereby interfering with anti-tumor immune reconstitution following radiotherapy and ultimately reducing HCC sensitivity to treatment (152). This evidence concerns the gene RECQL4 and hepatocellular carcinoma.